The ability of tumor cells to repair DNA damage is reduced following EGFR blockade with Cetuximab [14], and recently it has been demonstrated that the combination of EGFR inhibition and DNA damage-induced therapy increases in vitro and in vivo response of human tumor cells [19]. The gene discussed is EGFR; the disease is neoplasm.